Jackson Creek Investment Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Jackson Creek Investment Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-125,302	Closed	-$1.56M	–	319
2026 Q1	$1.56M	Sell	125,302 -96,831	-44%	-$1.3M	0.46%	103
2025 Q4	$2.8M	Sell	222,133 -10,358	-4%	-$119K	0.83%	2
2025 Q3	$2.33M	Sell	232,491 -96	-0%	-$862	0.67%	22
2025 Q2	$1.88M	Buy	232,587 +30,760	+15%	+$232K	0.51%	49
2025 Q1	$1.69M	Sell	201,827 -106	-0.1%	-$885	0.54%	27
2024 Q4	$1.6M	Sell	201,933 -6,273	-3%	-$52.6K	0.48%	68
2024 Q3	$1.73M	Buy	208,206 +46,446	+29%	+$363K	0.51%	50
2024 Q2	$1.03M	Buy	+161,760	New	+$1.03M	0.38%	134
2021 Q4	–	Sell	-199,960	Closed	-$1.07M	–	303
2021 Q3	$1.07M	Buy	199,960 +1,804	+0.9%	+$9.08K	0.4%	111
2021 Q2	$1.01M	Sell	198,156 -22,887	-10%	-$130K	0.38%	133
2021 Q1	$1.49M	Buy	+221,043	New	+$1.23M	0.52%	19

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Jackson Creek Investment Advisors's AMRX Position: Q2 2026 in Review

Jackson Creek Investment Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 125,302 shares — an estimated $1.56M sold.

Jackson Creek Investment Advisors first reported a position in AMRX in Q1 2021 and held it in 11 quarters. The position peaked at $2.8M in Q4 2025. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

Jackson Creek Investment Advisors reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jackson Creek Investment Advisors sold 125,302 Amneal Pharmaceuticals shares in Q2 2026, an estimated $1.56M.
Jackson Creek Investment Advisors first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Jackson Creek Investment Advisors's Amneal Pharmaceuticals position peaked at $2.8M in Q4 2025.
306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Jackson Creek Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.